Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
FAM114A1 influences cardiac pathological remodeling by regulating angiotensin II signaling
Kadiam C. Venkata Subbaiah, … , Wai Hong Wilson Tang, Peng Yao
Kadiam C. Venkata Subbaiah, … , Wai Hong Wilson Tang, Peng Yao
Published June 7, 2022
Citation Information: JCI Insight. 2022;7(13):e152783. https://doi.org/10.1172/jci.insight.152783.
View: Text | PDF
Research Article Cardiology

FAM114A1 influences cardiac pathological remodeling by regulating angiotensin II signaling

  • Text
  • PDF
Abstract

Cardiac pathological remodeling, a primary contributor to heart failure (HF) and death, is an important target for HF therapy. However, the signaling pathways that govern cardiac remodeling are not fully elucidated. Here, we found that a functionally unannotated human myocardial infarction–associated (MI-associated) gene, family with sequence similarity 114 member A1 (FAM114A1), is induced in failing human and mouse hearts compared with nonfailing hearts. Homozygous KO of Fam114a1 (Fam114a1–/–) in the mouse genome reduces cardiomyocyte hypertrophy, inflammation, and cardiac fibrosis while restoring cardiac function in angiotensin II–induced (Ang II–induced) and MI-induced HF mouse models. Cardiac fibroblasts (CFs) exhibit the highest FAM114A1 expression among different cardiac cell types. FAM114A1 is a critical autonomous factor for CF proliferation, activation, and migration. Mechanistically, FAM114A1 interacts with angiotensin receptor–associated protein (AGTRAP) and regulates the expression of angiotensin type 1 receptor (AT1R) and downstream Ang II signaling transduction, and it subsequently influences profibrotic response. Our results indicate that FAM114A1 regulates Ang II signaling, thereby activating CFs and other cardiac cells and augmenting pathological cardiac remodeling. These findings provide potentially novel insights into the regulation of cardiac remodeling and identify FAM114A1 as a therapeutic target for the treatment of heart disease.

Authors

Kadiam C. Venkata Subbaiah, Jiangbin Wu, Wai Hong Wilson Tang, Peng Yao

×

Figure 2

Deletion of FAM114A1 mitigates Ang II–induced cardiac remodeling and heart failure in mice.

Options: View larger image (or click on image) Download as PowerPoint
Deletion of FAM114A1 mitigates Ang II–induced cardiac remodeling and hea...
(A) Fam114a1–/– mice show reduced HW/TL (heart weight/tibia length) ratio after 4 weeks of Ang II infusion compared with WT mice. n = 6 for each group (male mice). (B) WGA staining of heart tissue sections of WT and Fam114a1–/– mice under Ang II or vehicle treatment. Cross-sectional area of CMs was measured and quantified. n = 6 hearts per group with 250–270 CMs measured per heart. Scale bar: 20 μm. (C) Picrosirius red staining of heart tissue sections of WT and Fam114a1–/– mice under Ang II or vehicle treatment. Scale bar: 1 mm. n = 6 for each group. (D) qPCR measurement of cardiac fibrosis and hypertrophy marker gene expression in WT and Fam114a1–/– hearts after 4 weeks of Ang II versus vehicle infusion. Rpl30 mRNA was used as a normalizer. n = 3 for each group. (E) Representative echocardiographic images suggest improved cardiac function in Fam114a1–/– mice compared with WT mice after Ang II or vehicle infusion. Quantification of ejection fraction (EF) and fractional shortening (FS) was shown. n = 6 for each group. Data are presented as mean ± SEM. Statistical significance was confirmed by 2-way ANOVA with Tukey’s multiple-comparison tests for A–E. *P < 0.05; **P < 0.01; ***P <0.001;.****P <0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts